{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:11:09Z","timestamp":1791274269625,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate adherence patterns, effectiveness, and sexually transmitted infection (STI) incidence among pre-exposure prophylaxis (PrEP) users in Germany and identify strategies to optimize HIV and STI prevention through individualized care and alternative PrEP modalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-site, pseudonymized prospective cohort study was conducted in Hamburg, Germany from December 2019 to September 2024. Clinical and laboratory data were linked with structured behavioral surveys from PrEP users at the University Medical Center Hamburg-Eppendorf.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 980 consented individuals, 589 initiated PrEP (median age 32\u00a0years, 97.1% male, and 81.8% were born in Germany). The mean follow-up was 102.3\u00a0weeks (IQR: 38.6\u2013151.4), totaling 1189.5 person-years. Daily users averaged 315\u00a0days of PrEP coverage per year (IQR: 293.0\u2013361.9\u00a0days), whereas on-demand users averaged 219\u00a0days (IQR: 138.4\u2013311.6\u00a0days), highlighting substantial variability in usage patterns. The overall dropout rate was 46.9%. No cases of HIV occurred during active PrEP use. STI incidence remained high 52.4 \/100 PY (95% CI: 47.8\u201357.4, n\u2009=\u2009421) for daily PrEP users, 38.9\/100 PY (95% CI: 30.1\u201349.5, n\u2009=\u200979) for event-driven users, predominantly due to\n                      <jats:italic>Chlamydia trachomatis<\/jats:italic>\n                      (21.1\/100 PY) and\n                      <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                      (18.8\/100 PY). Interest in long-acting PrEP was high (70%), especially among illicit substance users (OR 5.54). Renal function remained stable during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PrEP demonstrated high effectiveness despite heterogeneous risk burden and generally stable renal function. This supports flexible, person-centered models with simplified, risk-stratified monitoring and long-acting options. To extend impact beyond MSM, services should add multilingual access and women- and migrant-inclusive outreach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02667-w","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T09:11:40Z","timestamp":1761383500000},"page":"339-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Five-Year German PrEP cohort reveals high HIV protection and persistent STI burden: implications for individualized and flexible prevention strategies"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9912-7833","authenticated-orcid":false,"given":"Maher","family":"Almahfoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Weimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-2808","authenticated-orcid":false,"given":"Till","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8732-7085","authenticated-orcid":false,"given":"Hanna-Marie","family":"Weichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Hunstig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Grenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Scheiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-9224","authenticated-orcid":false,"given":"Marylyn M.","family":"Addo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-1938","authenticated-orcid":false,"given":"Julian","family":"Schulze zur Wiesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Degen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"2667_CR1","unstructured":"WHO (2022) Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030"},{"key":"2667_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","volume":"14","author":"RM Grant","year":"2014","unstructured":"Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(14)70847-3.","journal-title":"Lancet Infect Dis"},{"key":"2667_CR3","unstructured":"WHO (2012) Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV"},{"key":"2667_CR4","unstructured":"[DAIG] Deutsche AIDS-Gesellschaft [\u00d6AG] \u00d6sterreichische AIDS Gesellschaft Deutsch-\u00d6sterreichische Leitlinien zur HIV-Pr\u00e4expositionsprophylaxe-Klassifikation: S2k. AWMF-Register-Nr.: 055\u2013008"},{"key":"2667_CR5","unstructured":"European Medicines Agency (2016) First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU: Truvada to enhance existing HIV prevention strategies"},{"key":"2667_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-022-01699-y","author":"U Marcus","year":"2023","unstructured":"Marcus U, Schmidt D, Schink SB, Koppe U. Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use in Germany among men who have sex with men. J Public Health. 2023. https:\/\/doi.org\/10.1007\/s10389-022-01699-y.","journal-title":"J Public Health"},{"key":"2667_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1186\/s12889-024-19198-y","volume":"24","author":"D Schmidt","year":"2024","unstructured":"Schmidt D, Duport Y, Kollan C, et al. Dynamics of HIV PrEP use and coverage during and after COVID-19 in Germany. BMC Public Health. 2024;24:1691. https:\/\/doi.org\/10.1186\/s12889-024-19198-y.","journal-title":"BMC Public Health"},{"key":"2667_CR8","doi-asserted-by":"publisher","unstructured":"an der Heiden M, Marcus U, Kollan C, et al (2022) Sch\u00e4tzung der Anzahl von HIV-Neuinfektionen im Jahr 2021 und der Gesamtzahl von Menschen, die Ende 2021 mit HIV in Deutschland leben. Epidemiologisches Bulletin. https:\/\/doi.org\/10.25646\/10814","DOI":"10.25646\/10814"},{"key":"2667_CR9","doi-asserted-by":"publisher","unstructured":"Marcus U, Schmidt D, Friebe M, et al (2023) Gemeldete HIV-Erstdiagnosen 2021 \u2013 2022. Epidemiologisches Bulletin. https:\/\/doi.org\/10.25646\/11678","DOI":"10.25646\/11678"},{"issue":"1","key":"2667_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"J Lr","year":"2021","unstructured":"Lr J, Deborah D, E. CM, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. New England J Med. 2021;385(1):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","journal-title":"New England J Med"},{"key":"2667_CR11","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(22)00538-4.","journal-title":"Lancet"},{"key":"2667_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:1179\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2407001.","journal-title":"N Engl J Med"},{"issue":"1","key":"2667_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"F Kc","year":"2025","unstructured":"Kc F, Maribel A-Q, L. AA, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. New England J Med. 2025;392(1):1261\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2411858.","journal-title":"New England J Med"},{"key":"2667_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1097\/QAD.0000000000001859","volume":"32","author":"MJ Siedner","year":"2018","unstructured":"Siedner MJ, Hettema A, Hughey A, et al. Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland. AIDS. 2018;32:1541\u20132. https:\/\/doi.org\/10.1097\/QAD.0000000000001859.","journal-title":"AIDS"},{"key":"2667_CR15","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s10461-016-1565-9","volume":"21","author":"GJ Greene","year":"2017","unstructured":"Greene GJ, Swann G, Fought AJ, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2017;21:1336\u201349. https:\/\/doi.org\/10.1007\/s10461-016-1565-9.","journal-title":"AIDS Behav"},{"key":"2667_CR16","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s10461-016-1370-5","volume":"20","author":"JT Parsons","year":"2016","unstructured":"Parsons JT, Rendina HJ, Whitfield THF, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav. 2016;20:1390\u20139. https:\/\/doi.org\/10.1007\/s10461-016-1370-5.","journal-title":"AIDS Behav"},{"key":"2667_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/09540121.2024.2307378","volume":"36","author":"H Wang","year":"2024","unstructured":"Wang H, Zimmermann HML, van de Vijver D, Jonas KJ. Intention and preference to use long-acting injectable PrEP among MSM in the Netherlands: a diffusion of innovation approach. AIDS Care. 2024;36:89\u2013100. https:\/\/doi.org\/10.1080\/09540121.2024.2307378.","journal-title":"AIDS Care"},{"key":"2667_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/J.DRUGPO.2018.01.002","volume":"55","author":"M Rosi\u0144ska","year":"2018","unstructured":"Rosi\u0144ska M, Gios L, N\u00f6stlinger C, et al. Prevalence of drug use during sex amongst MSM in Europe: results from a multi-site bio-behavioural survey. Int J Drug Policy. 2018;55:231\u201341. https:\/\/doi.org\/10.1016\/J.DRUGPO.2018.01.002.","journal-title":"Int J Drug Policy"},{"key":"2667_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.DRUGPO.2017.10.008","volume":"52","author":"RW Glynn","year":"2018","unstructured":"Glynn RW, Byrne N, O\u2019Dea S, et al. Chemsex, risk behaviours and sexually transmitted infections among men who have sex with men in Dublin, Ireland. Int J Drug Policy. 2018;52:9\u201315. https:\/\/doi.org\/10.1016\/J.DRUGPO.2017.10.008.","journal-title":"Int J Drug Policy"},{"key":"2667_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061812","author":"M Coronado-Mu\u00f1oz","year":"2024","unstructured":"Coronado-Mu\u00f1oz M, Garc\u00eda-Cabrera E, Quintero-Fl\u00f3rez A, et al. Sexualized drug use and chemsex among men who have sex with men in Europe: a systematic review and meta-analysis. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13061812.","journal-title":"J Clin Med"},{"key":"2667_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/QAI.0000000000000868","volume":"71","author":"KK Mugwanya","year":"2016","unstructured":"Mugwanya KK, Wyatt C, Celum C, et al. Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis. JAIDS J Acquir Immune Defic Syndr. 2016;71:374\u201380. https:\/\/doi.org\/10.1097\/QAI.0000000000000868.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"2667_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamainternmed.2014.6786","volume":"175","author":"KK Mugwanya","year":"2015","unstructured":"Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1\u2013uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015;175:246\u201354. https:\/\/doi.org\/10.1001\/jamainternmed.2014.6786.","journal-title":"JAMA Intern Med"},{"key":"2667_CR23","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1016\/S2352-3018(22)00004-2","volume":"9","author":"R Schaefer","year":"2022","unstructured":"Schaefer R, da Costa A, Leite PH, Silva R, et al. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. Lancet HIV. 2022;9:e242\u201353. https:\/\/doi.org\/10.1016\/S2352-3018(22)00004-2.","journal-title":"Lancet HIV"},{"key":"2667_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00849744","volume":"6","author":"WE Snell","year":"1993","unstructured":"Snell WE, Fisher TD, Walters AS. The multidimensional sexuality questionnaire: an objective self-report measure of psychological tendencies associated with human sexuality. Annals of sex research. 1993;6:27\u201355. https:\/\/doi.org\/10.1007\/BF00849744.","journal-title":"Annals of sex research"},{"key":"2667_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-0031-128706","volume":"24","author":"K Brenk-Franz","year":"2011","unstructured":"Brenk-Franz K, Strau\u00df B. Der Multidimensionale Fragebogen zur Sexualit\u00e4t (MFS). Z Sexualforsch. 2011;24:256\u201371. https:\/\/doi.org\/10.1055\/s-0031-128706.","journal-title":"Z Sexualforsch"},{"key":"2667_CR26","doi-asserted-by":"publisher","unstructured":"Schmidt D, Ates Z, Friebe M, et al (2024) PrEP-Surveillance in Deutschland\u2013Ergebnisse der vierten halbj\u00e4hrlichen Befragung in HIV-Schwerpunkteinrichtungen. https:\/\/doi.org\/10.25646\/12927","DOI":"10.25646\/12927"},{"key":"2667_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-10174-4","author":"U Koppe","year":"2021","unstructured":"Koppe U, Marcus U, Albrecht S, et al. Barriers to using HIV pre-exposure prophylaxis (PrEP) and sexual behaviour after stopping PrEP: a cross-sectional study in Germany. BMC Public Health. 2021. https:\/\/doi.org\/10.1186\/s12889-021-10174-4.","journal-title":"BMC Public Health"},{"key":"2667_CR28","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s10508-024-02922-5","volume":"53","author":"F Valbert","year":"2024","unstructured":"Valbert F, Schmidt D, Kollan C, et al. Routine data analysis of HIV pre-exposure prophylaxis use and rates of sexually transmitted infections since coverage of HIV pre-exposure prophylaxis by the statutory health insurance in Germany. Arch Sex Behav. 2024;53:3663\u201372. https:\/\/doi.org\/10.1007\/s10508-024-02922-5.","journal-title":"Arch Sex Behav"},{"key":"2667_CR29","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.14.2100591","author":"H Streeck","year":"2022","unstructured":"Streeck H, Jansen K, Crowell TA, et al. HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019. Eurosurveillance. 2022. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.14.2100591.","journal-title":"Eurosurveillance"},{"key":"2667_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.930208","author":"M Uhrmacher","year":"2022","unstructured":"Uhrmacher M, Skaletz-Rorowski A, Nambiar S, et al. HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: results from a prospective observational study in Germany. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2022.930208.","journal-title":"Front Public Health"},{"key":"2667_CR31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/QAD.0000000000003889","volume":"38","author":"ES Wijstma","year":"2024","unstructured":"Wijstma ES, Jongen VW, Boyd A, et al. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project. AIDS. 2024;38:1248\u201356. https:\/\/doi.org\/10.1097\/QAD.0000000000003889.","journal-title":"AIDS"},{"key":"2667_CR32","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1016\/S2468-2667(20)30186-9","volume":"5","author":"N Hanum","year":"2020","unstructured":"Hanum N, Cambiano V, Sewell J, et al. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. Lancet Public Health. 2020;5:e501\u201311. https:\/\/doi.org\/10.1016\/S2468-2667(20)30186-9.","journal-title":"Lancet Public Health"},{"key":"2667_CR33","unstructured":"Statistisches Amt f\u00fcr Hamburg und Schleswig-Holstein (2024) Bev\u00f6lkerung mit Migrationshintergrund in den Hamburger Stadtteilen 2023. Statistischer Bericht A|10-j 23 HH"},{"key":"2667_CR34","unstructured":"Marcus U, Kollan C, Schmidt D, et al (2024) Sch\u00e4tzung der Anzahl der HIV-Neuinfektionen in den Jahren 2022 und 2023 sowie der Gesamtzahl der Menschen, die Ende 2023 mit HIV in Deutschland leben"},{"issue":"151","key":"2667_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004006","volume":"4","author":"PL Anderson","year":"2012","unstructured":"Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125. https:\/\/doi.org\/10.1126\/scitranslmed.3004006.","journal-title":"Sci Transl Med"},{"key":"2667_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208107","volume":"13","author":"RN Werner","year":"2018","unstructured":"Werner RN, Gaskins M, Nast A, Dressler C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection \u2013 a meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE. 2018;13:e0208107. https:\/\/doi.org\/10.1371\/journal.pone.0208107.","journal-title":"PLoS ONE"},{"key":"2667_CR37","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/OLQ.0b013e3182515601","volume":"39","author":"M Heiligenberg","year":"2012","unstructured":"Heiligenberg M, Wermeling PR, van Rooijen MS, et al. Recreational drug use during sex and sexually transmitted infections among clients of a city sexually transmitted infections clinic in Amsterdam, the Netherlands. Sex Transm Dis. 2012;39:518\u201327. https:\/\/doi.org\/10.1097\/OLQ.0b013e3182515601.","journal-title":"Sex Transm Dis"},{"key":"2667_CR38","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1369-1600.2010.00210.x","volume":"15","author":"S Pichini","year":"2010","unstructured":"Pichini S, Farr\u00e9 M, Abanades S, et al. Immunomodulating properties of gamma-hydroxybutyrate (GHB), flunitrazepam and ethanol in \u201cclub drugs\u201d users. Addict Biol. 2010;15:336\u201345. https:\/\/doi.org\/10.1111\/j.1369-1600.2010.00210.x.","journal-title":"Addict Biol"},{"key":"2667_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.0019-2805.2004.01847.x","volume":"111","author":"TJ Connor","year":"2004","unstructured":"Connor TJ. Methylenedioxymethamphetamine (MDMA, \u2019Ecstasy\u2019): a stressor on the immune system. Immunology. 2004;111:357\u201367. https:\/\/doi.org\/10.1111\/j.0019-2805.2004.01847.x.","journal-title":"Immunology"},{"key":"2667_CR40","doi-asserted-by":"publisher","DOI":"10.2196\/62801","volume":"10","author":"D Islek","year":"2024","unstructured":"Islek D, Sanchez T, Glick JL, et al. Preferences for starting daily, on-demand, and long-acting injectable HIV preexposure prophylaxis among men who have sex with men in the United States (2021-2022): nationwide online cross-sectional study. JMIR Public Health Surveill. 2024;10:e62801. https:\/\/doi.org\/10.2196\/62801.","journal-title":"JMIR Public Health Surveill"},{"key":"2667_CR41","doi-asserted-by":"publisher","DOI":"10.2196\/51023","volume":"12","author":"ML Groot Bruinderink","year":"2023","unstructured":"Groot Bruinderink ML, Boyd A, Coyer L, et al. Online-mediated HIV pre-exposure prophylaxis care and reduced monitoring frequency for men who have sex with men: protocol for a randomized controlled noninferiority trial (EZI-PrEP study). JMIR Res Protoc. 2023;12:e51023. https:\/\/doi.org\/10.2196\/51023.","journal-title":"JMIR Res Protoc"},{"key":"2667_CR42","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2352-3018(22)00126-6","volume":"9","author":"K Ngure","year":"2022","unstructured":"Ngure K, Ortblad KF, Mogere P, et al. Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial. Lancet HIV. 2022;9:e464\u201373. https:\/\/doi.org\/10.1016\/S2352-3018(22)00126-6.","journal-title":"Lancet HIV"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02667-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:49Z","timestamp":1770021589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02667-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2667"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02667-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.This study was approved by the University of Hamburg and the responsible local ethics committee of Hamburg.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all participants included in the study. All participants were informed about the publication of anonymized data. No person-related data were published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}